Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 2Diagnosis: Lung CancerNCT ID: NCT01746251
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-504
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug is still being studied. It also means that the FDA has not yet approved afatinib for use in patients. In this research study the investigators are looking to see if taking afatinib after surgery works better when taken over a short period of time, compared to a long period of time.
Conducting Institutions: Massachusetts General Hospital, Beth-Israel Deaconess Medical Center
Overall PI: Lecia Sequist, MD,
Massachusetts General Hospital
Site-responsible Investigators: Daniel Costa, MD,
Beth Israel Deaconess Medical Center
Contacts: Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060